Vimarsana
Biggest News Aggregation in the World

Page 11 - Late Stage Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Late Stage Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Late Stage Development Today - Breaking & Trending Today

Key Topics Not to be Missed at the Ophthalmic Drugs Conference - Vimarsana News

Key Topics Not to be Missed at the Ophthalmic Drugs Conference

SAE Media Group reports: join ophthalmic professionals for the Ophthalmic Drugs Conference this November.

Source: pr.com
FDA accepts priority review Seagen's sNDA for colorectal cancer medicine - Vimarsana News

FDA accepts priority review Seagen's sNDA for colorectal cancer medicine

The FDA has accepted for priority review Seagen’s sNDA seeking accelerated approval for its tukysa along with trastuzumab to treat colorectal cancer.

Tucatinib + Trastuzumab Granted Priority Review for HER2-Positive Metastatic Colorectal Cancer - Vimarsana News

Tucatinib + Trastuzumab Granted Priority Review for HER2-Positive Metastatic Colorectal Cancer

The FDA has accepted for Priority Review the sNDA for tucatinib plus trastuzumab for adults with HER2-positive colorectal cancer.

Source: empr.com
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedo - Vimarsana News

Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedo

– Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab –– Data highlighted in late-breaking presentation at the European Society for Medical Oncology (ESMO) Congress 2022 –BOTHELL, Wash. & TOKYO & RAHWAY, N.J.--(BU...

Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medic - Vimarsana News

Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medic

– Results from EV-103 trial evaluating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) in urothelial cancer to be featured as late-breaking oral session –BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its clinical development progra...